October 11, 2011
Lytix Biopharma was recently present at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. It was a successful conference with much attention to LTX-109 and especially its effect on nasal decolonisation.
Poster A2-029 "Evaluation of the In Vitro ADME Profile of LTX-109 - A Novel Antimicrobial Drug", B. Mortensen, A. Fugelli and W.M. Olsen.
Poster A2-030 "LTX-109 is Active against CA-MRSA (USA300) and S. pyogenes in a Mouse Skin Infection Model". W.M. Olsen, B. Mortensen, J.K. Khan, M. Rahman, J.S. Svendsen and A. Fugelli.
Poster A2-031 "Evaluation of the Preclinical Safety and Tolerability Profile of LTX-109 - A Novel Antimicrobial Drug". B. Mortensen, A. Fugelli and W.M. Olsen.
Poster C1-614 "LTX-109 Demonstrates Rapid Membranolytic Activity against Escherichia coli and Staphylococcus aureus". B. Mortensen, A. Fugelli, H.M. Blencke, K. Stensvåg, J.S. Svendsen and W.M. Olsen.
Poster E-1328 "In-vitro Activity of LTX-109 against Vancomycin Intermediate (VISA), Vancomycin Resistant (VRSA)and Mupirocin Susceptible, Low and High Level Resistant Strains of Staphylococcus aureus". Louis D. Saravolatz, MD, Joan Pawlak, BS, Leonard B. Johnson, MD, Mohammad G. Fakih, MD, Anders Fugelli, PhD, and Wenche M. Olsen, PhD
Poster L1-275 "LTX-109 is an Effective, Novel Agent for Nasal Decolonization of MRSA/MSSA - Results from a Phase I/IIa Study", W.M. Olsen, H. Wold, A. Nilsson, H. Janson, B. Mortensen, B. Iversen, A. Fugelli.